Abstract
Use of clinically active agents, such as kinase inhibitors, before nephrectomy is safe and feasible and can decrease the size of primary tumours, enabling optimization of the surgical approach. However, the overall clinical benefit of the neoadjuvant use of toxic drugs, such as axitinib, has not yet been demonstrated.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
Axitinib
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / surgery
-
Humans
-
Imidazoles / therapeutic use*
-
Indazoles / therapeutic use*
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / surgery
-
Neoadjuvant Therapy*
-
Nephrectomy
-
Protein Kinase Inhibitors / therapeutic use*
Substances
-
Antineoplastic Agents
-
Imidazoles
-
Indazoles
-
Protein Kinase Inhibitors
-
Axitinib